Intralesional BCG immunotherapy of pulmonary tumors

Candida albicans intralesional injection immunotherapy of warts.

Often, the treatment of verrucae is frustrating for both the physician and patient. Treatment may be painful, scarring, ineffective, and costly. The object of this study was to compare the clinical outcomes and safety of Candida albicans intralesional injection immunotherapy (CI) versus conventional wart treatment. The results of a prospective, nonrandomized, open-label, comparison study are pr...

BCG vaccine and pulmonary tuberculosis

Tuberculosis (TB) is one of the most important public health problems in the world and has been declared as a global emergency by the World Health Organization (WHO) in 1993. Bacillus Calmette-Guérin (BCG) is one of the first developed vaccines to prevent TB. Unfortunately, BCG vaccine has had a limited duration of protection and has shown controversial and variable levels of efficacy, especial...

Intralesional immunotherapy with Bacille Calmette-Guerin (BCG) vaccine for the treatment of warts: case report and systematic review

Bladder Cancer Immunotherapy: BCG and Beyond

Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the current standard of care, a significant proportion of patients fails or do not tolerate treatment. Th...

MR of recurrent high-grade astrocytomas after intralesional immunotherapy.

PURPOSE To describe the MR findings in six patients with recurrent cerebral astrocytomas before, immediately after, and 3 months after local immunotherapy with tumor-infiltrating lymphocytes and interleukin-2. METHODS Contrast-enhanced MR studies were obtained in six patients (three with anaplastic astrocytoma and three with glioblastoma multiforme) at the time of tumor recurrence, after a se...